Following news of RSV lower respiratory tract infections in infants immunized with Moderna’s investigational RNA vaccines, ...
Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...
Shares of Moderna Inc. MRNA sank 0.09% to $42.82 Thursday, on what proved to be an all-around dismal trading session for the ...
Shares of Moderna Inc. MRNA slipped 2.31% to $41.83 Friday, on what proved to be an all-around mixed trading session for the ...
In the chaotic early days of the pandemic, Wall Street scrambled to place bets on the companies that looked the most likely to thrive the uncharted waters that were rising all around us. The early ...
Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.
Moderna's (NASDAQ:MRNA) mRNA-1647, its vaccine asset for cytomegalovirus (CMV), may not yield positive interim phase 3 data ...
Norovirus vaccines face significant hurdles, with virtually no success from past efforts from HilleVax and Vaxxart. But ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 10.82% ...
2024 has been a generally outstanding year for the stock market, with the S&P 500 ( ^GSPC 0.82%) up by nearly 30% year to ...
The advisory committee, which met at the FDA’s request Thursday, did not reach a conclusion about the cause of a safety ...
Palantir, MicroStrategy, and Axon Enterprise are set to join the Nasdaq 100 Index on Monday, Dec. 23, replacing Super Micro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback